This biologic Ustekinumab was recently approved by the FDA for Crohn's - the stats on responders/remission are interesting to compare to Rem-L
So here they chose 628 patients who had failed to respond to conventional treatment, of those 397 responded to Ustekinumab and of those say 400 who responded approx 50% of them were in remission at 44 weeks - so your total numbers for remission are 200/628 or well less than 30%.
https://www.nejm.org/doi/full/10.1056/nejmoa1602773
oh and if you're interested have a look at the side effects profiles of the current treatments - most of these are immunosuppressants meaning you're at risk of TB or sepsis at best at worst increasing risk of serious cancers
https://www.webmd.com/ibd-crohns-disease/crohns-disease/crohns-biologics
Crohn’s Disease, page-50
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |